eligibility_summary
Eligible participants: patients who have previously received elranatamab, defined as having received at least one dose.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Drug/intervention: Elranatamab (ELREXFIO), a bispecific T‑cell–engaging monoclonal antibody (immunotherapy) that binds BCMA on myeloma cells and CD3 on T cells. Mechanism: Redirects and activates cytotoxic T cells via CD3/TCR signaling to form an immune synapse, release cytotoxic granules and cytokines, and kill BCMA+ malignant plasma cells. Targets: BCMA-expressing multiple myeloma cells, CD3 on T cells, downstream T‑cell activation/cytokine pathways (CRS/ICANS risk). Study: Non-interventional, real-world safety/efficacy in Japanese RRMM.